Danish pharmaceutical giant Novo Nordisk is taking compounding pharmacy iDexis to the Pretoria High Court. The highly anticipated legal battle will take place on June 10. The case focuses on the unauthorised scale production of semaglutide-based weight-loss injections. Novo Nordisk wants the court to stop iDexis from manufacturing, advertising, and distributing these products. The global firm alleges that iDexis is…